Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor ...

Blocking the MDM2–p53 interaction to reactivate wild-type p53 function is therefore a promising cancer therapeutic strategy, especially in this setting. At Boehringer Ingelheim, we have ...

Mosaic gained ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist, in the deal, which it hopes to advance in biomarker-defined indications.

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

Densitometric analysis was used to determine the intensity of p53, phospho-p53, and MDM2 bands. Results: Approximately 38.7% of the lung cancer patients examined had an association with wood smoke ...

Mosaic Therapeutics Ltd, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new ...

Mosaic Therapeutics, a Cambridge-based targeted oncology therapeutics company resolving cancer’s complexity with new ...

The orally-available MDM2-p53 agonist is designed to restore the function of p53, the most frequently mutated gene in cancer, which has so far resisted drug development efforts. The p53 gene ...